Pharmacokinetics of nitroglycerin and long-acting nitrate esters

The American Journal of Medicine
H L Fung

Abstract

The current literature on the human pharmacokinetics of nitroglycerin, isosorbide dinitrate, and isosorbide mononitrates is briefly reviewed and evaluated. The pharmacokinetics of nitroglycerin are unusual in that its systemic clearance is extremely large and that there is a distinct arterial-venous gradient in plasma concentration. These features had created substantial difficulties in the documentation and interpretation of nitroglycerin plasma concentrations and pharmacokinetics. Studies with isosorbide dinitrate showed that this nitrate is absorbed as intact drug at about 20 percent of a comparable intravenous dose, firmly disproving a previous belief that orally administered nitrate is completely degraded by presystemic metabolism. The current data suggest that plasma nitrate concentration may relate to some of its pharmacologic effects after short-term dosing, but the concentration-response relationship is complex after long-term dosing. Studies of nitrate pharmacokinetics in their presumed sites of action, namely, the vasculature, appear to be useful for the further understanding of the mechanism of action for these vasodilators.

References

Mar 1, 1979·Circulation·J Y Wei, P R Reid
May 1, 1979·Journal of Pharmaceutical Sciences·S T Horhota, H L Fung
Aug 1, 1976·The American Journal of Cardiology·J O ParkerP W Armstrong
May 1, 1973·Journal of Pharmaceutical Sciences·M T Rosseel, M G Bogaert
May 1, 1980·Canadian Journal of Physiology and Pharmacology·J A ArmstrongP W Armstrong
Apr 1, 1981·Anesthesiology·A B HillJ K Denlinger
Jun 1, 1983·British Journal of Clinical Pharmacology·H L Fung, J O Parker
Jun 1, 1982·Journal of Pharmaceutical Sciences·R A MorrisonE Jähnchen
Jan 1, 1981·European Journal of Clinical Pharmacology·U AbshagenB Kaufmann

❮ Previous
Next ❯

Citations

Oct 1, 1995·Catheterization and Cardiovascular Diagnosis·T M Marshall, A Dodek
Jan 3, 2012·Current Osteoporosis Reports·Sophie A Jamal, Celeste J Hamilton
Nov 16, 1987·The American Journal of Cardiology·H L Fung
Jun 13, 2001·Journal of the American College of Cardiology·Y Y ChirkovJ D Horowitz
Jan 15, 2014·BoneKEy Reports·Celeste J HamiltonSophie A Jamal
Jul 1, 1993·The American Review of Respiratory Disease·C A BrodkinL Rosenstock
Jun 1, 1993·Journal of Cardiothoracic and Vascular Anesthesia·J Van HemelrijckR Suy
Jul 1, 1985·American Heart Journal·H L Fung
Feb 1, 1984·International Journal of Cardiology·G D Curfman
Sep 1, 1984·The American Journal of Cardiology·J O Parker, H L Fung
Jun 22, 1984·The American Journal of Medicine·H L Fung
Jun 22, 1984·The American Journal of Medicine·J B YoungR Roberts
Jun 22, 1984·The American Journal of Medicine·J Abrams
Jan 1, 1989·Cardiovascular Drugs and Therapy·J O Parker
Sep 24, 1987·The New England Journal of Medicine·D C MayL D Hillis
Jun 25, 1987·The New England Journal of Medicine·J O Parker
Nov 1, 1985·The Journal of Pharmacy and Pharmacology·P A Cossum, M S Roberts
Nov 1, 1987·Drug Intelligence & Clinical Pharmacy·F P Zeller
Jan 1, 1985·Acta Medica Scandinavica. Supplementum·K Luomanmäki

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.